This means insulin is released only when blood glucose levels are elevated, reducing the risk of hypoglycaemia compared to some other diabetes medications
G., Jaja-Chimedza, A., Graf, B
Semaglutide has the strongest cardiovascular outcome data of any GLP-1 medication, with the SELECT trial demonstrating a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes
That does not mean the work is not paying off
A review paper by Gisbert and Calvet used meta-analysis of data published through 2010 to evaluate the role of rifabutin in H
While the therapy is still investigational, being informed and prepared as the clinical landscape evolves is a powerful step